BenzingaSeptember 23, 2026 at 5:11 AM NYLast Month
Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17
Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $18 to $17.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
